In Brief: Schering-Plough
Executive Summary
Schering-Plough: Company receives "approvable" letters from FDA for once-daily nasal spray Vancenase AQ Forte and Vanceril DS (Double Strength) inhaler formulations of the corticosteroid beclomethasone propionate for the treatment of rhinitis and asthma, respectively, company tells analysts in New York City June 21...